

Market Announcement

12 December 2019

Antisense Therapeutics Limited (ASX: ANP) – Trading Halt

Description

The securities of Antisense Therapeutics Limited ('ANP') will be placed in trading halt at the request of ANP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 16 December 2019 or when the announcement is released to the market.

Issued by

Cheng Tang

Senior Adviser, Listings Compliance (Melbourne)

Thursday 12 December 2019

Cheng Tang
Listings Compliance Advisor
ASX Melbourne

Email: Cheng.Tang@asx.com.au

Dear Cheng,

Request for Trading Halt for Antisense Therapeutics Limited

In accordance with ASX Listing Rule 17.1, the Company requests an immediate trading halt in respect of its securities (ASX Code: ANP), pending release of an announcement in relation to the preliminary results of the Company's ATL1102 for DMD Phase II clinical trial.

In requesting the trading halt, the Company provides the following information:

- The trading halt is requested in respect of finalising of an announcement following the Company's board review of the preliminary Phase II trial results
- Unless otherwise requested by the Company, ANP requests the trading halt to remain in place until the earlier of the release of an announcement or the morning of Monday 16 December 2019; and
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely,



Phillip Hains
Company Secretary

The Board authorise the request by the Company Secretary for this trading halt.